Tag: Pivotal

CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C (NPC). NPC is an ultra-rare, neurological disease caused by genetic mutations that result in lipid accumulation in cells, leading to visceral, neurological, and psychiatric symptoms. Arimoclomol is the only treatment shown to directly target the underlying pathology of NPC by increasing gene expression for improved lipid clearance. Arimoclomol for the treatment of NPC has been designated as an Orphan Medicinal Product by the EMA. Arimoclomol is marketed in the U.S. under the brand name MIPLYFFA®.

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- The Ontario Real Estate Association (OREA) Board of Directors is pleased to announce the appointment of Luigi Favaro as its new Chief Executive Officer (CEO), effective September 2, 2025. In this role, Favaro will lead the organization in its continued efforts to advocate on behalf of nearly 100,000 REALTOR® Members and support them in their pursuit of building stronger communities across the province.

Revenue Growth of 17.6% to HK$78.7 Million (US$10.1 million); Strong Cash Position of HK$84.9 Million (US$10.9 million)

Revenue Growth of 17.6% to HK$78.7 Million (US$10.1 million); Strong Cash Position of HK$84.9 Million (US$10.9 million)